Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01017146 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301
A Phase 3 study, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 744
- Enrollment target
NCT01017146 is a Phase 3 study that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 744 participants.
The verdict
NCT01017146, a Phase 3 study, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 744 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
Interventions
- DRUG Vehicle Foam
- DRUG Tazarotene foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01017146
The ClinicalTrials.gov registry entry for NCT01017146 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 744 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Foam is the first listed.
NCT01017146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01017146 about?
NCT01017146 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301". The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
What is the current status of trial NCT01017146?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 744 participants. The study started on 2009-10. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01017146?
The interventions under investigation include: Vehicle Foam (DRUG), Tazarotene foam (DRUG).
Who is sponsoring clinical trial NCT01017146?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.